Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$118.53 -2.7%	$119.67	$64.11 ▼ $139.13	$5.78B	1	652,952 shs	435,237 shs
BPMC Blueprint Medicines	$88.72 -1.1%	$98.13	$80.68 ▼ $121.90	$5.67B	0.58	726,248 shs	621,251 shs
SDGR Schrödinger	$19.96 -1.5%	$23.11	$16.67 ▼ $29.15	$1.46B	1.62	760,083 shs	856,997 shs
TLX Telix Pharmaceuticals Limited American Depositary Shares	$17.24 -1.5%	$17.92	$14.01 ▼ $30.36	$5.81B	N/A	26,380 shs	27,211 shs

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	0.00%	-6.51%	-7.06%	+39.81%	+48.53%
BPMC Blueprint Medicines	0.00%	0.00%	-8.13%	+2.19%	-6.47%
SDGR Schrödinger	0.00%	-8.44%	-10.53%	+6.06%	-26.07%
TLX Telix Pharmaceuticals Limited American Depositary Shares	0.00%	-3.09%	-4.12%	+7.08%	+1,723,999,900.00%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.7472 of 5 stars	4.5	3.0	0.0	4.5	2.1	4.2	0.6
BPMC Blueprint Medicines	2.7952 of 5 stars	4.3	1.0	0.0	0.0	3.6	0.8	0.6
SDGR Schrödinger	2.4299 of 5 stars	3.5	2.0	0.0	0.0	2.2	2.5	0.6
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.00	Buy	$167.64	41.43% Upside
BPMC Blueprint Medicines	2.70	Moderate Buy	$124.95	40.84% Upside
SDGR Schrödinger	3.00	Buy	$32.29	61.75% Upside
TLX Telix Pharmaceuticals Limited American Depositary Shares	3.00	Buy	$22.00	27.61% Upside

Current Analyst Ratings Breakdown

Latest SDGR, AXSM, TLX, and BPMC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/27/2025	AXSM Axsome Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$212.00 ➝ $216.00
3/20/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$120.00 ➝ $100.00
3/18/2025	BPMC Blueprint Medicines	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
3/17/2025	BPMC Blueprint Medicines	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$135.00
3/12/2025	TLX Telix Pharmaceuticals Limited American Depositary Shares	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/7/2025	BPMC Blueprint Medicines	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$150.00
3/6/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$200.00 ➝ $200.00
3/3/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$153.00 ➝ $153.00
3/3/2025	AXSM Axsome Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$132.00 ➝ $160.00
2/28/2025	BPMC Blueprint Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$128.00
2/27/2025	AXSM Axsome Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$125.00 ➝ $190.00

(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$385.69M	14.99	N/A	N/A	$1.18 per share	100.45
BPMC Blueprint Medicines	$508.82M	11.14	N/A	N/A	$4.67 per share	19.00
SDGR Schrödinger	$207.54M	7.02	$0.53 per share	37.42	$7.60 per share	2.63
TLX Telix Pharmaceuticals Limited American Depositary Shares	$783.21M	7.42	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.99	N/A	42.03	N/A	-74.47%	-223.51%	-39.88%	5/5/2025 (Estimated)
BPMC Blueprint Medicines	-$67.09M	-$1.08	N/A	136.49	N/A	-13.19%	-77.49%	-20.84%	5/1/2025 (Estimated)
SDGR Schrödinger	$40.72M	-$2.57	N/A	N/A	N/A	-91.84%	-35.77%	-24.51%	4/29/2025 (Estimated)
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	0.00	35.92	N/A	N/A	N/A	N/A	N/A

Latest SDGR, AXSM, TLX, and BPMC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
2/26/2025	Q4 2024	SDGR Schrödinger	-$0.35	-$0.55	-$0.20	-$0.55	$83.20 million	$88.32 million
2/20/2025	Q4 2024	BPMC Blueprint Medicines	-$0.68	-$0.79	-$0.11	-$0.79	N/A	N/A
2/18/2025	Q4 2024	AXSM Axsome Therapeutics	-$0.97	-$0.96	+$0.01	-$1.54	$117.83 million	$118.77 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
SDGR Schrödinger	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	3.22	2.11	2.04
BPMC Blueprint Medicines	1.15	2.85	2.80
SDGR Schrödinger	N/A	4.11	4.11
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
BPMC Blueprint Medicines	N/A
SDGR Schrödinger	79.05%
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.40%
BPMC Blueprint Medicines	4.21%
SDGR Schrödinger	8.60%
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	48.77 million	37.84 million	Optionable
BPMC Blueprint Medicines	640	63.91 million	61.22 million	Optionable
SDGR Schrödinger	790	73.04 million	66.59 million	Optionable
TLX Telix Pharmaceuticals Limited American Depositary Shares	N/A	336.87 million	N/A	N/A

SDGR, AXSM, TLX, and BPMC Headlines

Recent News About These Companies

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Trading Down 4.4% - Here's What Happened

March 28 at 12:17 PM | marketbeat.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Trading 4.4% Higher - Here's Why

March 23, 2025 | americanbankingnews.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Trading Up 4.4% - Should You Buy?

March 22, 2025 | marketbeat.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Up - Still a Buy?

March 21, 2025 | marketbeat.com

Telix Pharmaceuticals Gets FDA Approval for Prostate Cancer Screening Agent

March 21, 2025 | investopedia.com

FDA Approves New Prostate Cancer Imaging Agent Gozellix®

March 21, 2025 | globenewswire.com

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America

March 17, 2025 | globenewswire.com

What is William Blair's Estimate for TLX FY2025 Earnings?

March 15, 2025 | marketbeat.com

Research Analysts Set Expectations for TLX FY2027 Earnings

March 14, 2025 | marketbeat.com

William Blair Reaffirms Outperform Rating for Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX)

March 13, 2025 | marketbeat.com

Telix Adds Lead-212 Isotope Production Capability

March 12, 2025 | globenewswire.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Gap Down - Time to Sell?

March 12, 2025 | marketbeat.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Sees Strong Trading Volume - Time to Buy?

March 11, 2025 | marketbeat.com

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Shares Up 4.3% - Here's Why

March 7, 2025 | marketbeat.com

Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum

March 3, 2025 | globenewswire.com

FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review

February 25, 2025 | globenewswire.com

Recruitment Spotlight: Phase 3 Clinical Trial of Novel Prostate Cancer Radiopharmaceutical Now Active in Miami

February 25, 2025 | globenewswire.com

Telix Pharmaceuticals Limited (TLX) Upgraded to Buy: What Does It Mean for the Stock?

February 24, 2025 | zacks.com

What Makes Telix Pharmaceuticals Limited (TLX) a Good Fit for 'Trend Investing'

February 24, 2025 | zacks.com

Australia's Telix Pharmaceuticals scales record peak on upbeat revenue forecast

February 20, 2025 | reuters.com

Telix Pharmaceuticals Limited 2024 Q4 - Results - Earnings Call Presentation

February 20, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SDGR, AXSM, TLX, and BPMC Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$118.53 -3.24 (-2.66%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$118.76 +0.23 (+0.20%)

As of 03/28/2025 07:00 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Blueprint Medicines NASDAQ:BPMC

$88.72 -1.01 (-1.13%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$88.70 -0.02 (-0.02%)

As of 03/28/2025 04:08 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Schrödinger NASDAQ:SDGR

$19.96 -0.30 (-1.48%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$19.82 -0.15 (-0.73%)

As of 03/28/2025 06:50 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Telix Pharmaceuticals Limited American Depositary Shares NASDAQ:TLX

$17.24 -0.27 (-1.54%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$17.26 +0.02 (+0.12%)

As of 03/28/2025 04:05 PM Eastern

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time